<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03971877</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2016/45</org_study_id>
    <nct_id>NCT03971877</nct_id>
  </id_info>
  <brief_title>Detection of Colistin-resistant Isolates From Patients of Intensive Care Units and Oncohaematology Wards.</brief_title>
  <acronym>RESCO</acronym>
  <official_title>Detection of Colistin-resistant Isolates From Patients Admitted in Intensive Care Units and Oncohaematology Wards in the Region Nouvelle Aquitaine: Diagnostic Accuracy of the Detection Methods, Estimation of the Prevalence and Description of the Resistance Mechanisms.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The increasing use of colistin in multidrug resistant strains, as Enterobacteriaceae
      producing extended-spectrum β-lactamases or carbapenemases, is associated with the emergence
      of colistin resistant isolates. The main objective of this project is to estimate the
      diagnostic accuracy (sensitivity and specificity) of a new rapid detection test of colistin
      resistant strains (Rapid Polymyxin NP test) isolated in clinical settings.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For 15 years, the prevalence of the extended-spectrum β-lactamases producing
      Enterobacteriaceae (ESBLE), resistant to the 3rd generation cephalosporins, has constantly
      increased worldwide. Since 2010 an additional threat appeared with the emergence of the
      bacteria resistant to carbapenems, the antibiotic of choice in case of infection due to
      ESBLE. To treat the infection due to these extremely resistant strains, there are still only
      few molecules, as the colistin. Very quickly, the colistin resistance appeared, especially a
      plasmid-born resistance described in December 2015 and which has already spread a lot, most
      probably from an animal reservoir. The control of the resistance dissemination requires
      reliable tools for detection of colistin resistant isolates, in particular in
      immunocompromised patients, as those of intensive care unit (ICU) or oncohaematology ward,
      that are often exposed to multidrug resistant strains. Currently, the colistin resistance is
      difficult to detect and that is probably why it was underestimated for a long time and has
      already diffuse worldwide. Some recent tests for the detection of colistin resistant isolates
      have been developed and tested in laboratory. They have now to be evaluated in clinical
      situation in order to be correctly used and interpreted. From rectal swabs of patients
      admitted in ICU and oncohaematology ward, investigators will use first a new culture medium
      (SuperPolymyxin) for screening the colistin resistant Gram negative bacteria and then a new
      rapid test (Rapid Polymyxin NP test) to confirm this resistance. These tests will be compared
      to the reference test of MIC (Minimal Inhibitory Concentration) determined by the broth
      micro-dilution (BMD) method. The isolates will be collected on the screening medium, during
      12 months, from 4 centers (Mont de Marsan, Limoges, Dax, Bordeaux) and sent to Bordeaux
      University Hospital where the rapid test and the BMD method will be centralized.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 16, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of Rapid Polymyxin NP test</measure>
    <time_frame>Up to 1 year after Inclusion (rectal swab or stool collection)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity of Rapid Polymyxin NP test</measure>
    <time_frame>Up to 1 year after Inclusion (rectal swab or stool collection)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence rate of the colistin resistance</measure>
    <time_frame>Up to 1 year after Inclusion (rectal swab or stool collection)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacterial species found resistant</measure>
    <time_frame>Up to 1 year after Inclusion (rectal swab or stool collection)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of the various colistin resistance mechanisms</measure>
    <time_frame>Up to 1 year after Inclusion (rectal swab or stool collection)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of the genetic support of the resistance (plasmid or chromosome)</measure>
    <time_frame>Up to 1 year after Inclusion (rectal swab or stool collection)</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">6360</enrollment>
  <condition>Colistin Resistance in Bacteria</condition>
  <arm_group>
    <arm_group_label>Patients admitted in ICU or oncohaematology ward</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Rapid Polymyxin NP test</intervention_name>
    <description>From rectal swabs of patients admitted in ICU and oncohaematology ward, investigators will use first a new culture medium (SuperPolymyxin) for screening the colistin resistant Gram negative and then a new rapid test (Rapid Polymyxin NP test) to confirm this resistance. These tests will be compared to the reference test of MIC (Minimal Inhibitory Concentration) determined by the broth micro-dilution (BMD) method.</description>
    <arm_group_label>Patients admitted in ICU or oncohaematology ward</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Colistin resistant isolates from rectal swabs or stools
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted in ICU or in oncohaematology ward
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients ≥ 18 years old

          -  patients admitted in ICU or in oncohaematology ward

        Exclusion Criteria:

        - Patients under protection of justice
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul PEREZ, MD-PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Unité de Soutien Méthodologique à la Recherche Clinique et Epidémiologique (USMR) du CHU de Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rupestre ZANNOU</last_name>
    <phone>0557821536</phone>
    <phone_ext>+33</phone_ext>
    <email>rupestre.zannou@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Véronique DUBOIS, PharmD-PhD</last_name>
    <phone>0556795667</phone>
    <phone_ext>+33</phone_ext>
    <email>veronique.dubois@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rupestre ZANNOU</last_name>
      <phone>0557821536</phone>
      <phone_ext>+33</phone_ext>
      <email>rupestre.zannou@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Véronique DUBOIS, MD-PhD</last_name>
      <phone>0556795667</phone>
      <phone_ext>+33</phone_ext>
      <email>veronique.dubois@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Véronique DUBOIS, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Dax</name>
      <address>
        <city>Dax</city>
        <zip>40107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine CHRISMENT, MD</last_name>
      <phone>0558356608</phone>
      <phone_ext>+33</phone_ext>
      <email>chrismentd@ch-dax.fr</email>
    </contact>
    <investigator>
      <last_name>Delphine CHRISMENT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie-Cécile PLOY, MD-PhD</last_name>
      <phone>0555056166</phone>
      <phone_ext>+33</phone_ext>
      <email>marie-cecile.ploy@unilim.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Cécile PLOY, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Mont de Marsan</name>
      <address>
        <city>Mont-de-Marsan</city>
        <zip>40024</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bouchra LOUTFI, MD</last_name>
      <phone>0558051984</phone>
      <phone_ext>+33</phone_ext>
      <email>bouchra.loutfi@ch-mt-marsan.fr</email>
    </contact>
    <investigator>
      <last_name>Bouchra LOUTFI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 29, 2019</study_first_submitted>
  <study_first_submitted_qc>May 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>January 20, 2020</last_update_submitted>
  <last_update_submitted_qc>January 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colistin resistance in bacteria</keyword>
  <keyword>Rectal swab</keyword>
  <keyword>ICU</keyword>
  <keyword>Oncohaematology</keyword>
  <keyword>Gram negative bacteria</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polymyxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

